Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Comparison of EGF and FGF2 Serum Levels with Epithelization and Fibroblast Histopathology on the Acceleration of Deep Dermal Burn Injury Healing using the Combination of PRP and SVF in Wistar Rats.

Mahir AF., Laidding SR., Zainuddin AA., Mariana N., Syarif S., Islam AA.

Laboratory Study with a reported sample of 64 on Chronic Wound, Burns, published in Ann Burns Fire Disasters (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Ann Burns Fire Disasters (2025)
Country
Italy
Reported sample size
64
Source database
PubMed
PMID
40589714
PMCID
PMC12186180
DOI
10.1155/2015/684084
Citations
57

Abstract (original English)

Burn injuries cause a considerable number of fatalities in Indonesia annually. Platelet-rich plasma (PRP) in combination with stromal vascular fraction (SVF) is a stem cell-related treatment modality for deep dermal burn wound healing that utilizes growth factors such as the epidermal growth factor (EGF) and basic fibroblast growth factor (FGF2). This study aimed to assess the relationship between serum EGF and FGF2 levels and their impact on re-epithelialization and fibroblast histopathology during deep dermal burn wound healing using PRP and SVF. Wistar rats (n=64) were categorized into the following groups: PRP+SVF injection (Group A), topical PRP+SVF application (Group B), topical Vaseline application (Group C), or control (Group D). Treatments were evaluated on days 1, 4, 7, 10 and 14 post-treatment for the treatment groups and day 0 for the control group. The software SPSS 22 was used for the statistical analysis, along with the Shapiro-Wilk, independent t-test, Mann-Whitney, Kruskal-Wallis, one-way ANOVA, and Kendall's Tau-B tests. The results showed that Group A exhibited the highest FGF2 and EGF levels (6.62 and 8.10 ng/ml, respectively), closely followed by Group B (6.40 and 7.09 ng/ml, respectively). Group C had lower FGF2 levels than Group D and similar EGF levels. The PRP+SVF injection group displayed faster re-epithelialization and fibroblast proliferation. The PR

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
CorneaStem CellsHumansBurnsStem Cell TransplantationWound Healing

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research